Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.

Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma that has been associated with a poor prognosis. Despite improvements in frontline management strategies, including the incorporation of cytarabine, intensification of chemotherapeutic regimens, and consolidation with transplant, MCL remains incurable. Our current understanding of MCL biology affords the opportunity to investigate novel, molecularly targeted therapeutic approaches. This review will focus on innovative drug development for the treatment of relapsed or refractory MCL, including therapies aimed at disrupting the B-cell receptor signaling pathway, regulators of apoptosis, and immunomodulators.

[1]  Jeffrey A Jones,et al.  Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non‐Hodgkin's lymphoma , 2014, American journal of hematology.

[2]  W. Wilson,et al.  Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. , 2013, Blood.

[3]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[4]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[5]  C. Flowers,et al.  Using primary site as a predictor of survival in mantle cell lymphoma , 2013, Cancer.

[6]  Sonali M. Smith,et al.  An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA , 2013, Leukemia & lymphoma.

[7]  G. Salles,et al.  CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.

[8]  J. Drach,et al.  Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study , 2012 .

[9]  A. D. Van den Abbeele,et al.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. , 2012, Blood.

[10]  L. Staudt,et al.  Pathogenetic importance and therapeutic implications of NF‐κB in lymphoid malignancies , 2012, Immunological reviews.

[11]  A. Rosenwald,et al.  The complex landscape of genetic alterations in mantle cell lymphoma. , 2011, Seminars in cancer biology.

[12]  M. Czuczman,et al.  Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response , 2011, British journal of haematology.

[13]  A. Rosenwald,et al.  Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. , 2011, Blood.

[14]  M. Amiot,et al.  ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents , 2011, Clinical Cancer Research.

[15]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.

[16]  John D. Roberts,et al.  Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms , 2011, Clinical Cancer Research.

[17]  A. Wiestner,et al.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.

[18]  R. Ulrich,et al.  Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma , 2010 .

[19]  L. Staudt,et al.  Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. , 2010, Blood.

[20]  Michael L. Wang,et al.  Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma , 2010, British journal of haematology.

[21]  G. Mulligan,et al.  Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial , 2010, Leukemia & lymphoma.

[22]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[23]  Thomas S. Lin,et al.  Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Byrd,et al.  Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Calaminici,et al.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. , 2009, Blood.

[26]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Renata Walewska,et al.  Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma* , 2009, Molecular & Cellular Proteomics.

[28]  E. Kimby,et al.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.

[29]  C. Flowers,et al.  Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma , 2008, Bone Marrow Transplantation.

[30]  George Muller,et al.  Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.

[31]  C. Doglioni,et al.  Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. , 2008, Blood.

[32]  J. Raemaekers,et al.  A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  S. Alkan,et al.  Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment. , 2006, Leukemia research.

[34]  J. Leonard,et al.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Gascoyne,et al.  A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  E. Jaffe,et al.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.

[37]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[38]  A. Zelenetz,et al.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[40]  G. Mcmahon,et al.  VEGF receptor signaling in tumor angiogenesis. , 2000, The oncologist.

[41]  R. Advani,et al.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Leonard,et al.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.